96 related articles for article (PubMed ID: 26892232)
1. Challenging immunosuppression treatment in lung transplant recipients with kidney failure.
Högerle BA; Kohli N; Habibi-Parker K; Lyster H; Reed A; Carby M; Zeriouh M; Weymann A; Simon AR; Sabashnikov A; Popov AF; Soresi S
Transpl Immunol; 2016 Mar; 35():18-22. PubMed ID: 26892232
[TBL] [Abstract][Full Text] [Related]
2. Basiliximab with delayed introduction of calcineurin inhibitors as a renal-sparing protocol following liver transplantation in children with renal impairment.
Mouzaki M; Yap J; Avinashi V; Babu A; Fu A; Deangelis M; Van Roestel K; Ghanekar A; Kamath B; Avitzur Y; Fecteau A; Jones N; Ling S; Grant D; Ng V
Pediatr Transplant; 2013 Dec; 17(8):751-6. PubMed ID: 24118898
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
[TBL] [Abstract][Full Text] [Related]
4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
5. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
6. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
[TBL] [Abstract][Full Text] [Related]
7. Initial data on basiliximab in critically ill children undergoing heart transplantation.
Ford KA; Cale CM; Rees PG; Elliott MJ; Burch M
J Heart Lung Transplant; 2005 Sep; 24(9):1284-8. PubMed ID: 16143246
[TBL] [Abstract][Full Text] [Related]
8. Belatacept for renal rescue in lung transplant patients.
Timofte I; Terrin M; Barr E; Sanchez P; Kim J; Reed R; Britt E; Ravichandran B; Rajagopal K; Griffith B; Pham S; Pierson RN; Iacono A
Transpl Int; 2016 Apr; 29(4):453-63. PubMed ID: 26678245
[TBL] [Abstract][Full Text] [Related]
9. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency.
Verna EC; Farrand ED; Elnaggar AS; Pichardo EM; Balducci A; Emond JC; Guarrera JV; Brown RS
Transplantation; 2011 Jun; 91(11):1254-60. PubMed ID: 21617588
[TBL] [Abstract][Full Text] [Related]
10. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
11. Initial immunosuppression with or without basiliximab: a comparative study.
Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R
Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457
[TBL] [Abstract][Full Text] [Related]
12. Posterior reversible encephalopathy syndrome after kidney transplantation in pediatric recipients: Two cases.
Giussani A; Ardissino G; Belingheri M; Dilena R; Raiteri M; Pasciucco A; Colico C; Beretta C
Pediatr Transplant; 2016 Feb; 20(1):68-71. PubMed ID: 26607205
[TBL] [Abstract][Full Text] [Related]
13. CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen.
Thibault G; Paintaud G; Legendre C; Merville P; Coulon M; Chasseuil E; Ternant D; Rostaing L; Durrbach A; Di Giambattista F; Büchler M; Lebranchu Y
Transpl Int; 2016 Feb; 29(2):184-95. PubMed ID: 26369526
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
15. Once-daily oral administration of cyclosporine in a lung transplant patient with a history of renal toxicity of calcineurin inhibitors.
Matsuda Y; Chen F; Miyata H; Date H
Interact Cardiovasc Thorac Surg; 2014 Jul; 19(1):171-3. PubMed ID: 24659549
[TBL] [Abstract][Full Text] [Related]
16. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
Arora S; Gude E; Sigurdardottir V; Mortensen SA; Eiskjær H; Riise G; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Aukrust P; Solbu D; Iversen M; Gullestad L
J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment: Results of a Pilot Study (PATRON07).
Schnitzbauer AA; Sothmann J; Baier L; Bein T; Geissler EK; Scherer MN; Schlitt HJ
Transplantation; 2015 Dec; 99(12):2565-75. PubMed ID: 26018348
[TBL] [Abstract][Full Text] [Related]
18. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]